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Abstract. We recently isolated a cDNA clone encod-
ing a functional platelet thrombin receptor that defined
a unique mechanism of receptor activation. Thrombin
cleaves its receptor's extracellular amino terminal ex-
tension, unmasking a new amino terminus that func-
tions as a tethered peptide ligand and activates the re-
ceptor. A novel peptide mimicking this new amino
terminus was a full agonist for platelet secretion and
aggregation, suggesting that this unusual mechanism
accounts for platelet activation by thrombin. Does this
mechanism also mediate thrombin's assorted actions
on non-platelet cells? We now report that the novel
W
E recently isolated a cDNA clone encoding a func-
tional thrombin receptor by expressing cloning in
Xenopus oocYtes (23) . The library used was made
from Dami cells, a megakaryocyte-like cell line, and the
clone was shown to be expressed by platelets. The clone en-
codes a seven transmembrane domain receptor with a one
hundred-residue extracellular amino terminal extension.
This extracellular extension contains a putative thrombin
cleavage site (LDPR/S ; / represents the point of cleavage) re-
sembling the known thrombin cleavage site found in the
thrombin-activated zymogenprotein C (LDPR/I). Structure-
activity studies with the cloned receptor (10, 22, 23) strongly
suggest a unique mechanism of receptor activation. Throm-
bin cleaves its receptor at the LDPR/S cleavage site unmask-
ing a new amino terminus beginning with the sequence
SFLL . . . ; this new amino terminus then functions as a teth-
ered peptide ligand, binding to an as yet undefined site in the
body of the thrombin receptor, effecting receptor activation.
A peptide mimicking this new amino terminus was a full
agonist for platelet secretion and aggregation, supporting the
model of receptor activation proposed above and suggesting
that this unusual mechanism accounts for platelet activation
by thrombin (22) .
In addition to its critical role in activating platelets to effect
hemostasis and thrombosis (8), thrombin has potent actions
on a variety of non-platelet cell types (reviewed in 16) . For
example, thrombin has potent chemotactic activities for
monocytes (1) and is mitogenic for several cell types (3, 4),
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thrombin receptor agonist peptide reproduces thrombin-
induced events (specifically, phosphoinositide hydrolysis
and mitogenesis) in CCL-39 hamster lung fibroblasts,
a naturally thrombin-responsive cell line. Moreover,
these thrombin-induced events could be recapitulated
in CV-1 cells, normally poorly responsive to thrombin,
after transfection with human platelet thrombin recep-
tor cDNA . Our data show that important thrombin-
induced cellular events are mediated by the same
unusual mechanism of receptor activation in both plate-
lets and fibroblasts, very likely via the same or very
similar receptors.
actions that may play important roles in inflammatory and
proliferative processes in vivo. Are these assorted activities
of thrombin also mediated by the unusual receptor activation
mechanism described above? Do multiple receptors mediate
thrombin's diverse actions, or does the cloned "platelet
thrombin receptor" also account for thrombin-induced
events in non-platelet cell types? To begin to address these
questions, we took two approaches. First, the hamster lung
fibroblast cell line CCL-39 is knownto respond to thrombin
with robust activation of the phosphoinositide turnover sig-
naling pathway and with mitogenesis (11, 14, 15). We asked
whether the novel thrombin receptor agonist peptide de-
scribed above would elicit these two important thrombin-
induced events in this naturally thrombin-responsive cell
line. As implied above, the thrombin receptor is in essence
a peptide receptor; the agonist peptide bypasses thrombin-
mediated receptor proteolysis and activates the thrombin
receptor independent of thrombin and its protease activity.
Agonist peptide caused both phosphoinositide hydrolysis
and mitogenesis in CCL-39 cells. We next transfected CV-1
cells, which are normally poorly responsive to thrombin,
with the platelet thrombin receptor cDNA. Expressionofthe
cloned platelet thrombin receptor in CV-1 cells reproduced
the responses normally seen in CCL-39 cells, both throm-
bin-induced phosphoinositide hydrolysis and mitogenesis. In
both cell types, thrombin- and agonist peptide-induced phos-
phoinositide hydrolysis was largely pertussis toxin insensi-
tive. Thus activation of two important thrombin-induced
827events in CCL-39 fibroblasts occurs via the same unusual ac-
tivation mechanism used for platelet activation, and very
likely via the same or a very similar receptor.
Materials andMethods
Peptides
Agonist peptide SFLLRNPNDKYEPF and control peptides LLRNPN-
DKYEPF and FSLLRNPNDKYEPF were synthesized by UCSFs Biomo-
lecular Resource Facility (San Francisco, CA) or were a generous gift from
Robert Scarborough, COR Therapeutics, Inc. (South San Francisco, CA).
Peptides were purified by reverse phase HPLC before use.
Receptor-expressing CellLines
A cDNA encoding a functional human platelet thrombin receptor was sub-
cloned into pBJI, an expression vector derived from pcDL-SRa296 (19)
(pBJI was agenerous gift from Dr. Mark Davis). The expression construct
was cotransfected with a neomycin selection marker (18) into CV-1 cells by
lipofection (6). Cells were grownin DME with 10% FCS, 100 U/ml penicil-
lin, and 100 pg/ml streptomycin. Stable transfectants were isolated using
neomycin analogue G418 at concentrations of0.8 mg/ml. Individual clones
were selected and screened by dot blot for expression ofthrombin receptor
mRNA. The highest expressing clones were expanded and used in subse-
quent phosphoinositide turnover assays.
PhosphoinosiddeHydrolysisAssays
Cells were seeded into 12-well plates at a density of 105 cells per well and
grown to confluence. Wells were then rinsed once with 2 ml DME contain-
ing 25 mM Hepes, 100 U/ml penicillin, and 100 pg/ml streptomycin. Cells
were then incubated with 0.5 nil of DME containing 25 mM Hepes buffer,
pH 7.4, 100 U/ml penicillin, and 100 mg/ml streptomycin, and 2 ACi/ml
[3H]myoinositol for 20-24h at 37°C. Cells were treated with LiCl (20 mM
final concentration) I min beforeaddition ofagonist. After 15 min ofagonist
treatment, all wells were rinsed once with 1 ml cold PBS, and cells were
then extracted with 750 p120 mM formic acid for 30 min at 4°C. In all ex-
periments involving the used of Bordetella pertussis toxin islet-activating
protein (List Biological Laboratories, Campbell, CA), cells were incubated
at 37°C for 5 h before agonist addition in the presence of pertussis toxin
at a final concentration of 100 ng/ml.
Cell extracts were loaded onto 1 ml packed volume columns of anion-
exchange gel resin AG1X8, formate form, 100-200 mesh size (Bio-Rad
Laboratories, Cambridge, MA) after columns were prepared with sequen-
cial washes of2 nil 2 M ammonium formate/0.1 M formic acid, 2 nil water,
and 4 ml 20 mM NH40H, pH 9.0. Immediately after loading, columns
were washed with 3 m140 mM NH40H, pH 9.0, followed by 4 m140 mM
ammonium formate. Columns were then eluted with 4 ml 2 M ammonium
formate/0.1 M formic acidinto scintillationvials containing 10 nil of scintil-
lation cocktail and vials were counted in a scintillation counter (Beckman
Instruments, Palo Alto, CA) for 10 min each. This procedure collects inosi-
tol mono, bis, and tris phosphates (11).
MitogenesisAssays
CCL-39 cells and CV-1 cells were grown to confluence in 96 well plates
(Costar, Cambridge, MA) in 100 AI DME (Gibco Laboratories, Grand Is-
land, NY) containing 10% FCS, 25 mM Hepes buffer, pH 7.4, 100 U/ml
penicillin, and 100 pg/ml streptomycin. Cells were then rinsed inDME and
incubated in 100 pl DME containing 25 mM Hepes buffer, pH 7.4, 100
U/ml penicillin, and 100 pg/ml streptomycin for 48 h. Agonist was then
added with or without 1 pg/atl insulin, 5 pg/nil transferrin, and 0.5 mg/ml
BSA (see Fig. 2) and the incubation continued for 12 h. At this time
[3H]thymidine was added at 1.0 ACi/well (see Fig. 2) or 5.0 ACi/well. TCA-
insoluble radioactivity was determined after an additional 24-h incubation.
Transfected and untransfected CV-1 cells (see Fig. 5) were treated with
[3H]thynildine (0.5 ACi/well) and agonists simultaneously and the plates
incubated for an additional 48 h at 37°C. [3H]thymidine incorporation into
TCAinsoluble material was determined as previously described (5).
[3H]thymidine uptake results were confirmed by determining percent posi-
tive nuclei by [3H]thymidine autoradiography as previously described (5).
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ADPRibosylation
Membrane preparation and ADP ribosylation was performed essentially as
previously described (2). Thrombin receptor-transfected CV-1 cells were
grown to confluence in eight 100-nmi plates. Four of these plates were in-
cubated in the presence of pertussis toxin (100 ng/ml final concentration)
for 5 h at 37°C. Cells were then harvested using calcium/magnesium-free
PBS with 0.4% EDTA, pelleted by centrifugation at 1,000 rpm for 10 min,
resuspendedin 800 pl of lysis buffer (50 mM Tris-HCI, pH 7.5, 2.5 mm
M9C12, 1 mM EGTA, 1 mM PMSF, 1 mM DTT, and 1 mM benzamidine-
HCI) and lysed by freeze thawing and shearing through a 27-gauge needle.
Cell nuclei were pelleted by centrifugation at 1,000 rpm for 5 min at 4°C
and the membrane-containing supernatant was removed and centrifuged at
14,000 rpm for 20 min at 4°C. The membrane-containing pellet was
resuspended in 200 Al lysis buffer supplemented with 10% glycerol and pro-
tein concentrations were determined using Bradford reagent. 50 Ag of per-
tussis toxin-treated or -untreated membranes were suspended in 30 pl of 50
mM Tris-HCI, pH 7.5, 1 mM EDTA, and 1 MM MgCIZ and to each sample
was added 50 pl 2x reaction buffer (2 mM ATP, 100 mM Tris-HCI, pH
7.4, 20 mM thymidine, 40 mM arginine, 0.4 mg/ml BSA, 200 mM KP04,
pH 7.5, 10 mM ADP-ribose, 20 MM M9C12, 2 mM EUTA, and 200 AM
GTP) and 4 Al activated pertussis toxin (pertussis toxin was activated by
incubating 20 gl pertussis toxin [1 mg/ml] with 20 p142 mM DTT, 20 mM
Tris-HCI, pH 7.5 at 30°C for 20 min). Finally, 10 Al of5 AM NAD contain-
ing 20 ACi [32P]NAD was added to each sample and incubated at 30°C for
30 min. The reaction was stopped by adding 100 Al of NAD wash solution
(5 mM NAD, 50 mM Tris-HCI, pH 7.5, 25 mM EDTA) to each sample.
Membranes were pelleted by centrifugation at 14,000 rpm for 5 min,
washed twice with 200 Al NAD wash solution, resuspended in 100 Al
Laemmli sample buffer, boiled for 5 min, and analyzed by SDS-PAGE (12 %
acrylamide gel) and autoradiograph. Exposure time was 5 h.
Results andDiscussion
Agonist peptide caused phosphoinositide hydrolysis in CCL-
39 cells with an EC,,, of -10 AM (Fig. 1 A). The EC50 for
thrombin-induced phosphoinositide hydrolysis in CCL-39
cells was -30 pM (Fig. 1 B) . The relative potencies of
agonist peptide and thrombin in this system mimicked that
seen for agonist-induced responses mediated by the cloned
receptor in the oocyte system (22) . Moreover, maximum re-
sponses elicited by saturating concentrations of agonist pep-
tide (100 AM) or thrombin (1 nM) were similar (Fig. 1, A
and B). Thrombin receptor agonist peptide also stimulated
[3H]thymidine uptake in CCL-39 fibroblasts by approxi-
mately 20-fold (Fig. 2), and was once again several logs less
potent than thrombin. The lower potency of agonist peptide
compared to thrombin is predictable giventhe current model
of receptor activation. Thrombin acts enzymatically; the
peptide acts by binding. Thrombin generates a tethered
ligand; the peptide is free. The kinetic advantagesfor throm-
bin are apparent.
The specificity of the agonist peptide was confirmed in sev-
eral ways. First, a control peptide missing the agonist pep-
tide's first two amino acids (see Materials and Methods) did
not stimulate mitogenesis or phosphoinositide hydrolysis in
CCL-39 cells (data not shown), even at concentrations as
high as 100 AM. Second, another control peptide in which
the first two amino acids were switched in positions
(SFLLRNPNDKYEPF to FSLLRNPNDKYEPF) had only
minimal agonist activity (Fig. 2). Lastly, the actions of the
agonist peptide were receptor dependent in the transfection
studies discussed below.
The actions of the thrombin receptor agonist peptide de-
scribed above strongly suggested that thrombin-induced
phosphoinositide hydrolysis and mitogenesis in CCL-39
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Figure 1. Thrombin-induced and thrombin receptor agonist pep-
tide-induced phosphoinositide hydrolysis in CCL-39 fibroblasts .
Quiesced CCL-39 fibroblasts loaded with [3H]myoinositol (see
Materials and Methods) were treated in the presence of 20 mM
LiCl for 15 min at 37°C with thrombin receptor agonist peptide (A)
or a-thrombin (B) at the concentrations indicated . Total [3H]inos-
itol phosphates were collected and quantitated as described in
Materials and Methods . Each point represents the mean of three
replicate determinations with standard deviations as shown . These
results are representative of three replicate experiments .
cells are mediated, at least in part, by the same novel proteo-
lytic mechanism of receptor activation seen in platelets,
probably by the same or closely related receptors. Northern
analysis of mRNA from CCL-39 fibroblasts suggested that
the hamster homologue of the cloned human platelet throm-
bin receptor was expressed in this hamster fibroblast cell line
(Fig. 3) as recently reported (12) . Interestingly, Pouysségur
and colleagues have reported that thrombin receptor agonist
peptide elicited robust mitogenic effects on their subclone of
CCL-39 cells only when FGF was included in the medium,
while thrombin itself was mitogenic in the absence ofFGF
(21) . We have not observed a requirement for additional mi-
togens for the action of agonist peptide on the CCL-39 cells
used in our laboratory (Fig . 2) . We do wish to state, how-
ever, that our data in no way preclude the existence ofother
thrombin receptors .
To determine whether the clonedhuman platelet thrombin
receptor could itself account for thrombin-induced cellular
events in non-platelet cells, thrombin receptor cDNA was
stably transfected into CV-1 cells and the ability of receptor-
transfected cells to respond to both a-thrombin and throm-
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Figure 2 . Thrombin and thrombin receptor agonist peptide cause
mitogenesis in CCL-39 fibroblasts . CCL-39 fibroblasts were in-
cubated in either serum-free DME (open columns) or serum-free
DME with lug/ml insulin, 5 /g/ml transferrin, and 0.5 mg/mlBSA
(closed columns) for 48 h at 37°C . Cells were then stimulated with
either a-thrombin, thrombin receptor agonist peptide (SFLLRN-
PNDKYEPF ; SFLL), or control peptide (FSLLRNPNDKYEPF ;
FSLL) at the concentrations indicated for 12 h at 37°C, followed
by addition of [3H]thymidine in the continued presence of agonists
for an additional 24 h at 37°C . [3H]thymidine incorporation into
TCA-insoluble material was determined as previously described
(5) . Each point represents the mean of three replicate determina-
tions with standard deviations as shown. These results were
replicated in three separate experiments . Similar results were ob-
tained when the [3H]thymidine concentration was increased five-
fold, such that [ 3H]thymidine could not be limiting.
Figure 3 Detection of thrombin
receptor mRNA in CCL-39 fi-
broblasts. Five micrograms of
poly(A)+ RNA from CCL-39
fibroblasts was denatured in gly-
oxal-DMSO and subjected to
Northern analysis using standard
techniques (13) . The blot was hy-
bridized at high stringency with
random primer-generated 32P_-la-
beled probe representing the en-
tire coding region of the cloned
humanplatelet thrombin receptor ;
hybridized probe was detected by
autoradiography. Themigration of
28S and 18SRNA isshown atright .A
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Figure 4. Transfection with platelet thrombin receptorcDNA con-
fers thrombin-induced and thrombin receptor agonist peptide-
induced phosphoinositide hydrolysis on CV -1 cells . Thrombin
receptor-transfected (e) and untransfected (o) CV -1 cells labeled
with [3H]myoinositol (see Materials and Methods) were treated in
the presence of 20mM LiCl for 15 min at 37°C with a-thrombin
(A) or thrombin receptor agonist peptide (B) at the concentrations
indicated . Total [ 3H]inositol phosphates were collected and quan-
titated as described in Materials and Methods. [3H]inositol phos-
phate release induced by 0.001 nM «-thrombin was equivalent to
baseline (i.e ., did not stimulate inositol phosphate release) . Each
point represents the mean of three replicate determinations with
standard deviations as shown . These results are representative of
three replicate experiments.
bin receptor agonist peptide was examined . CV-1 cells trans-
fected with thehuman platelet thrombin receptor responded
with a 400% increase in inositol phosphate release when
stimulated with saturating concentrations of either thrombin
or agonist peptide (Fig . 4,A and B) . The ECso's for thrombin
and thrombin receptor agonist peptide were 100pM and 10
AM, respectively, similar to the EC so's found in naturally
thrombin-responsive CCL-39 cells and in oocytes express-
ing the platelet thrombin receptor cDNA (22) . By contrast,
untransfected CV-1 cells exhibited no significant increase in
phosphoinositide hydrolysis when stimulated with either
thrombin or thrombin receptor agonist peptide at concentra-
tions as high as 100 nM and 300 AM, respectively (Fig . 4,
A and B) . Thrombin failed to activate phosphoinositide turn-
over in other clones expressing thrombin receptor mutants
rendered unactivatable by cleavage site mutations (Hung,
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Figure S. Transfection with platelet thrombin receptorcDNA con-
fers thrombin-induced and thrombin receptor agonist peptide-in-
duced mitogenesis on CV -1 cells. Quiesced thrombin receptor-
transfected (9) and untransfected (o) CV -1 cells were stimulated
with the indicated concentrations of a-thrombin for 48 h at 37°C
and [ 3H]thymidine incorporation into TCA-insoluble material was
determined as previously described (5) . Mean cpm per well ofun-
stimulated receptor-transfected and -untransfected cells were simi-
lar (5,940 f 738 [S.E.] and 6,566 t 1,447 [S.E.], respectively) .
D. T., T.-K. H . Vu, and S . R . Coughlin, manuscript in prep-
aration) . While anticipated from our previous studies (22),
this is the first demonstration that the cloned thrombin recep-
tor couples to phosphoinositide hydrolysis .
Figure 6. Demonstration of a lack of pertussis substrate in mem-
branes from pertussis toxin-treated cells. Membranes from per-
tussis toxin-treated (+) or untreated (-) thrombin receptor-trans-
fectedCV -1 cells were analyzed for available pertussis substrates as
described in Materials and Methods . Quantitation of radioactivity
in the + lane band and in the corresponding region of the - lane
revealed thatatleast97% ofpertussis substrate had been "removed"
by pertussis toxin pretreatment .C
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The cloned "platelet thrombin receptor" also conferred
thrombin-induced mitogenesis to CV-1 cells. [3H]thymidine
uptake in CV-1 cells stably transfected with the cloned
thrombin receptor cDNA increased -500% in response to
thrombin, while untransfected CV-1 cells showed minimal
response (Fig. 5).
These studies show that transfection of CV-1 cells with the
cloned platelet thrombin receptor cDNA conferred the throm-
bin responses seen in naturally thrombin-responsive CCL-
39 cells. The similarities in the thrombin and peptide re-
sponses in native CCL-39 cellsand receptor-transfected CV-1
cells extended to their pertussis toxin sensitivity. Pertussis
toxin treatment sufficient to fully ADP-ribosylate available
G-protein a subunits (Fig. 6) had little inhibitory effect on
thrombin- or agonist peptide-stimulated phosphoinositide
hydrolysis in thrombin receptor-transfected CV-1 cells (Fig.
7, A andB). In CCL-39 cells, pertussis toxin treatment caused
only partial inhibition ofthrombin- or agonist peptide-stimu-
lated phosphoinositide hydrolysis (Figure 7, C and D). Pub-
lished studies report both pertussis-sensitive and -insensitive
thrombin-induced phosphoinositide hydrolysis in various
cell lines (7, 9, 11, 14, 15), suggesting that the thrombin re-
ceptor may couple to phosphoinositide hydrolysis via differ-
ent G-proteins determined by a cell's G-protein repertoire,
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Figure 7 Thrombin-induced and thrombin receptor agonist peptide-induced phosphoinositide hydrolysis in thrombin receptor-transfected
CV-1 cells and CCL-39 fibroblasts is largely pertussis toxin-insensitive. Quiesced thrombin receptor-transfected CV-1 cells (A and B) or
CCL-39 fibroblasts (C and D) labeled with [3H]myoinositol (see Materials and Methods) were incubated at 37°C for 5 h with either 10 Al
of PBS (o) or an equal volume of PBS containing pertussis toxin to yield a final concentration 100 ng/nil (e). Cells were then treated
for 15 minutes at 37°C with a-thrombin (A and C) and thrombin receptor agonist peptide (B and D) at the concentrations indicated in
the presence of 20 mM LiCl. Total [3H]inositol phosphates were collected and quantitated as described in Materials and Methods. Each
point represents the mean of three replicate determinations with standard deviations as shown. These results are representative of three
replicate experiments.
or thatdifferent receptors may exist. Our studies demonstrate
that the cloned thrombin receptor couples to phosphoinosi-
tide hydrolysis predominantly via a pertussis toxin-insensi-
tive G-protein(s) in the cell lines we examined. The recently
described Gq class of G-proteins, which lack a "pertussis
site (17) and couple to the /31 isozyme of phospholipase C
(20), are candidates for mediating thrombin receptor-induced
phosphoinositide hydrolysis.
In summary, these studies suggest that the unique mecha-
nism of thrombin receptor activation described for platelet
activation also mediates important thrombin-induced events
(phosphoinositide hydrolysis and mitogenesis) in a naturally
thrombin-responsive fibroblast cell line. Moreover, our
studies show that the platelet thrombin receptor can confer
these same responses to a cell line that is normally poorly
responsive to thrombin. Our results strongly suggest that the
hamster homologue of the cloned human "platelet thrombin
receptor" accounts, at least in part, for thrombin responses
in CCL-39 fibroblasts and that the cloned platelet thrombin
receptor may mediate not only platelet activation but also
mitogenesis and other thrombin-induced events in a variety
of cell types. In this context, we have recently found throm-
bin receptor mRNA expressed in vascular endothelium and
smooth muscle cells by PCR and Northern analysis (22, anddata not shown) and by in situ hybridization of human arter-
ies (data not shown) . Thus antagonists of the cloned throm-
bin receptormay be useful not only in inhibiting platelets and
thrombosis, but also in blocking undesirable thrombin-
induced inflammatory or proliferative responses in the blood
vessel wall.
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